Endotoxin binding by sevelamer: Potential impact on nutritional status

International Journal of Nephrology

Volumn 2013, Issue , 2013, Pages

  Kubotera, Natsuki ^a   Prokopienko, Alexander J ^a   Garba, Adinoyi O ^a   Pai, Amy Barton ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873370538     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2013/954956     Document Type: Review

References (52)

1. Stenvinkel P., Alvestrand A., Inflammation in end-stage renal disease: sources, consequences, and therapy. Seminars in Dialysis 2002 15 5 329 337 2-s2.0-0036719916 10.1046/j.1525-139X.2002.00083.x
2. Ikizler T. A., Wingard R. L., Harvell J., Shyr Y., Hakim R. M., Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney International 1999 55 5 1945 1951 2-s2.0-0032920541 10.1046/j.1523-1755.1999.00410.x (Pubitemid 29197983)
3. Carrero J. J., Qureshi A. R., Axelsson J., Avesani C. M., Suliman M. E., Kato S., Bárány P., Snaedal-Jonsdottir S., Alvestrand A., Heimbürger O., Lindholm B., Stenvinkel P., Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. The American Journal of Clinical Nutrition 2007 85 3 695 701 2-s2.0-33847791922 (Pubitemid 46393499)
4. Don B. R., Kaysen G., Serum albumin: relationship to inflammation and nutrition. Seminars in Dialysis 2004 17 6 432 437 2-s2.0-12144269577 10.1111/j.0894-0959.2004.17603.x (Pubitemid 40110428)
5. Raj D. S., Carrero J. J., Shah V. O., Qureshi A. R., Bárány P., Heimbürger O., Lindholm B., Ferguson J., Moseley P. L., Stenvinkel P., Soluble CD14 Levels, Interleukin 6, and mortality among prevalent hemodialysis patients. The American Journal of Kidney Diseases 2009 54 6 1072 1080 2-s2.0-70449631288 10.1053/j.ajkd.2009.06.022
6. Kalantar-Zadeh K., Block G., McAllister C. J., Humphreys M. H., Kopple J. D., Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. The American Journal of Clinical Nutrition 2004 80 2 299 307 2-s2.0-4344560597 (Pubitemid 41080002)
7. Ikizler T. A., Pupim L. B., Brouillette J. R., Levenhagen D. K., Farmer K., Hakim R. M., Flakoll P. J., Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. The American Journal of Physiology 2002 282 1 E107 E116 2-s2.0-0036079322 (Pubitemid 34654113)
8. Vannini F. D., Antunes A. A., Caramori J. C. T., Martin L. C., Barretti P., Associations between nutritional markers and inflammation in hemodialysis patients. International Urology and Nephrology 2009 41 4 1003 1009 10.1007/s11255-009-9563-8
9. Anker S. D., Ponikowski P., Varney S., Chua T. P., Clark A. L., Webb-Peploe K. M., Harrington D., Kox W. J., Poole-Wilson P. A., Coats A. J. S., Wasting as independent risk factor for mortality in chronic heart failure. The Lancet 1997 349 9058 1050 1053 2-s2.0-0030972278 10.1016/S0140-6736(96)07015-8 (Pubitemid 27158249)
10. McIntyre C. W., Harrison L. E. A., Eldehni M. T., Jefferies H. J., Szeto C. C., John S. G., Sigrist M. K., Burton J. O., Hothi D., Korsheed S., Owen P. J., Lai K. B., Li P. K. T., Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clinical Journal of the American Society of Nephrology 2011 6 1 133 141 2-s2.0-79251486009 10.2215/CJN.04610510
11. Beutler B., Rietschel E. T., Innate immune sensing and its roots: the story of endotoxin. Nature Reviews Immunology 2003 3 2 169 176 2-s2.0-0037317763 10.1038/nri1004 (Pubitemid 37328694)
12. Ward R. A., New AAMI standards for dialysis fluids. Nephrology News & Issues 2011 25 13 33 36
13. Arizono K., Nomura K., Motoyama T., Matsushita Y., Matsuoka K., Miyazu R., Takeshita H., Fukui H., Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purification 2004 22 supplement 2 26 29 2-s2.0-12544259226 10.1159/000081870
14. Hsu P. Y., Lin C. L., Yu C. C., Chien C. C., Hsiau T. G., Sun T. H., Huang L. M., Yang C. W., Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients: a prospective cross-over study. Journal of Nephrology 2004 17 5 693 700 2-s2.0-16644365043
15. Feroze U., Kalantar-Zadeh K., Sterling K. A., Benner D., Shah V., Becker K., Kovesdy C. P., Raj D. S., Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. Journal of Renal Nutrition 2012 22 3 317 326 10.1053/j.jrn.2011.05.004
16. Genth-Zotz S., von Haehling S., Bolger A. P., Kalra P. R., Wensel R., Coats A. J. S., Anker S. D., Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. The American Journal of Cardiology 2002 90 11 1226 1230 2-s2.0-0036890211 10.1016/S0002-9149(02)02839-4 (Pubitemid 35346880)
17. Gonclaves S., Pecoits-Filho R., Perreto S., Fluid overload is associated with endotoxinemia but not with systemic inflammation in chronic kidney disease patients. Journal of the American Society of Nephrology 2005 16 470A
18. Perianayagam M. C., Jaber B. L., Endotoxin-binding affinity of sevelamer hydrochloride. The American Journal of Nephrology 2008 28 5 802 807 2-s2.0-51149108771 10.1159/000135691
19. Sun P. P., Perianayagam M. C., Jaber B. L., Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study. Journal of Renal Nutrition 2009 19 5 432 438 2-s2.0-68949175617 10.1053/j.jrn.2009.01.022
20. Stinghen A. E. M., Gonçalves S. M., Bucharles S., Branco F. S., Gruber B., Hauser A. B., Pecoits-Filho R., Sevelamer decreases systemic inflammation in parallel to a reduction in endotoxemia. Blood Purification 2010 29 4 352 356 2-s2.0-77950031877 10.1159/000302723
21. van Amersfoort E. S., van Berkel T. J. C., Kuiper J., Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clinical Microbiology Reviews 2003 16 3 379 414 2-s2.0-0038447123 10.1128/CMR.16.3.379-414.2003 (Pubitemid 36871313)
22. Raetz C. R. H., Whitfield C., Lipopolysaccharide endotoxins. Annual Review of Biochemistry 2002 71 635 700 2-s2.0-0035997382 10.1146/annurev. biochem.71.110601.135414 (Pubitemid 34800232)
23. Zanoni I., Ostuni R., Capuano G., Collini M., Caccia M., Ronchi A. E., Rocchetti M., Mingozzi F., Foti M., Chirico G., Costa B., Zaza A., Ricciardi-Castagnoli P., Granucci F., CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation. Nature 2009 460 7252 264 268 2-s2.0-67650500800 10.1038/nature08118
24. Zanoni I., Ostuni R., Marek L. R., Barresi S., Barbalat R., Barton G. M., Granucci F., Kagan J. C., CD14 controls the LPS-induced endocytosis of toll-like receptor 4. Cell 2011 147 4 868 880 10.1016/j.cell.2011.09.051
25. Hauser A. B., Azevedo I. R. F., Gonçalves S., Stinghen A., Aita C., Pecoits-Filho R., Sevelamer carbonate reduces inflammation and endotoxemia in an animal model of uremia. Blood Purification 2010 30 3 153 158 2-s2.0-77956855146 10.1159/000319850
26. Noori N., Kovesdy C. P., Dukkipati R., Feroze U., Molnar M. Z., Bross R., Nissenson A. R., Kopple J. D., Norris K. C., Kalantar-Zadeh K., Racial and ethnic differences in mortality of hemodialysis patients: role of dietary and nutritional status and inflammation. The American Journal of Nephrology 2011 33 2 157 167 2-s2.0-79551559576 10.1159/000323972
27. Powers K. A., Kapus A., Khadaroo R. G., Papia G., Rotstein O. D., 25% albumin modulates adhesive interactions between neutrophils and the endothelium following shock/resuscitation. Surgery 2002 132 2 391 398 2-s2.0-0036676868 10.1067/msy.2002.126508 (Pubitemid 35024790)
28. Kitano H., Fukui H., Okamoto Y., Kikuchi E., Matsumoto M., Kikukawa M., Morimura M., Tsujita S., Nagamoto I., Nakatani T., Takaya A., Tsujii T., Role of albumin and high-density lipoprotein as endotoxin-binding proteins in rats with acute and chronic alcohol loading. Alcoholism Clinical and Experimental Research 1996 20 1, supplement 73A 76A 2-s2.0-0030010515
29. Kotanko P., Carter M., Levin N. W., Intestinal bacterial microflora-a potential source of chronic inflammation in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2006 21 8 2057 2060 2-s2.0-33748086020 10.1093/ndt/gfl281 (Pubitemid 44295025)
30. Ding L. A., Li J. S., Gut in diseases: physiological elements and their clinical significance. World Journal of Gastroenterology 2003 9 11 2385 2389 2-s2.0-0345330239
31. Krack A., Sharma R., Figulla H. R., Anker S. D., The importance of the gastrointestinal system in the pathogenesis of heart failure. European Heart Journal 2005 26 22 2368 2374 2-s2.0-27644438235 10.1093/eurheartj/ehi389 (Pubitemid 41552965)
32. Bullen J. J., Rogers H. J., Spalding P. B., Ward C. G., Iron and infection: the heart of the matter. FEMS Immunology and Medical Microbiology 2005 43 3 325 330 2-s2.0-13644251505 10.1016/j.femsim.2004.11.010 (Pubitemid 40228944)
33. Boelaert J. R., Daniels R. F., Schurgers M. L., Matthys E. G., Gordts B. Z., van Landuyt H. W., Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrology Dialysis Transplantation 1990 5 2 130 134 2-s2.0-0025230292 (Pubitemid 20154871)
34. Walter T., Olivares M., Pizarro F., Muñoz C., Iron, anemia, and infection. Nutrition Reviews 1997 55 4 111 124 2-s2.0-0030871962 (Pubitemid 27296373)
35. Ashrafian H., Hepcidin: the missing link between hemochromatosis and infections. Infection and Immunity 2003 71 12 6693 6700 2-s2.0-0344420199 10.1128/IAI.71.12.6693-6700.2003 (Pubitemid 37475295)
36. Robson K. J., Hepcidin and its role in iron absorption. Gut 2004 53 5 617 619 2-s2.0-2342421100 10.1136/gut.2003.027631 (Pubitemid 38561433)
37. Pai A. B., Depczynski J., Pai M. P., McQuade C. R., Mercier R. C., Non-transferrin-bound iron is associated with enhanced Staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. The American Journal of Nephrology 2006 26 3 304 309 2-s2.0-33746354586 10.1159/000094343 (Pubitemid 44114402)
38. Raj D. S. C., Shah V. O., Rambod M., Kovesdy C. P., Kalantar-Zadeh K., Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. The American Journal of Kidney Diseases 2009 54 6 1062 1071 2-s2.0-70449670853 10.1053/j.ajkd.2009.06.028
39. Terawaki H., Yokoyama K., Yamada Y., Maruyama Y., Iida R., Hanaoka K., Yamamoto H., Obata T., Hosoya T., Low-grade endotoxemia contributes to chronic inflammation in hemodialysis patients: examination with a novel lipopolysaccharide detection method. Therapeutic Apheresis and Dialysis 2010 14 5 477 482 2-s2.0-77957346206 10.1111/j.1744-9987.2010.00815.x
40. Wanner C., Drechsler C., Krane V., C-reactive protein and uremia. Seminars in Dialysis 2009 22 4 438 441 2-s2.0-69249105316 10.1111/j.1525-139X. 2009.00596.x
41. Kumar A., Haery C., Parrillo J. E., Myocardial dysfunction in septic shock. Critical Care Clinics 2000 16 2 251 287 2-s2.0-0034112616 (Pubitemid 30193850)
42. Wrong O., Harland C., Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. Nephron Physiology 2007 107 1 17 33 2-s2.0-34548457654 10.1159/000106568 (Pubitemid 47360951)
43. Barna M. M., Kapoian T., O'Mara N. B., Sevelamer carbonate. Annals of Pharmacotherapy 2010 44 1 127 134 2-s2.0-74549184101 10.1345/aph.1M291
44. Genzyme Corporation, Renagel (Sevelamer Hydrochloride) Package Insert 2011 Cambridge, Mass, USA Genzyme Corporation
45. Genzyme Corporation, Renvela (Sevelamer Carbonate) Package Insert 2011 Cambridge, Mass, USA Genzyme Corporation
46. Braunlin W., Zhorov E., Guo A., Apruzzese W., Xu Q., Hook P., Smisek D. L., Mandeville W. H., Holmes-Farley S. R., Bile acid binding to sevelamer HCl. Kidney International 2002 62 2 611 619 2-s2.0-0035991563 10.1046/j.1523-1755. 2002.00459.x (Pubitemid 34779775)
47. Pai A. B., Shepler B. M., Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 2009 29 5 554 561 2-s2.0-66249108582 10.1592/phco.29.5.554
48. Autissier V., Damment S. J. P., Henderson R. A., Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride. Journal of Pharmaceutical Sciences 2007 96 10 2818 2827 2-s2.0-35348938594 10.1002/jps.20956 (Pubitemid 47597830)
49. Navarro-González J. F., Mora-Fernández C., de Fuentes M. M., Donate-Correa J., Cazaña-Pérez V., García-Pérez J., Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clinical Journal of the American Society of Nephrology 2011 6 9 2272 2279 10.2215/CJN.01650211
50. Vlassara H., Uribarri J., Cai W., Pyzik R., Post J., Grosjean F., Woodward M., Striker G. E., Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clinical Journal of the American Society of Nephrology 2012 7 6 934 942 10.2215/CJN.12891211
51. Suki W. N., Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. Journal of Renal Nutrition 2008 18 1 91 98 2-s2.0-37049000335 10.1053/j.jrn.2007.10.019 (Pubitemid 350251835)
52. Di Iorio B., Bellasi A, Russo D., Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clinical Journal of the American Society of Nephrology 2012 7 3 487 493 10.2215/CJN.03820411